<DOC>
	<DOCNO>NCT01686789</DOCNO>
	<brief_summary>The study aim study outcome pharmacokinetics-adjusted dose ribavirin ( plus pegIFN ) SVR chronic HCV patient .</brief_summary>
	<brief_title>Randomized Controlled Open Label Trial Peg Alpha 2a Interferon Adjusted-dose Ribavirin vs. Standard Therapy Treatment Naive Chronic Hepatitis C Patients Infected With Genotype 4</brief_title>
	<detailed_description>Background : The introduction Peg interferon Ribavirin ( oral nucleoside analogue ) chronic Hepatitis C lead concept chronic hepatitis C ( HCV ) curable disease . Improvement treatment efficacy still major challenge . Optimal Ribavirin dose essential achieve SVR ( sustained virological response ) . A recent trial show significantly high sustain virological response ( SVR ) patient receive 15.2 mg/kg/day Ribavirin compare 13.3 mg/kg/day . Ribavirin give combination Peg interferon alpha-2b ( 1 ) . A small pilot study , 10 patient Chronic Hepatitis C genotype 1 treated Ribavirin dosage 3600 mg/day- mean 2540 mg/day- plus Peg-interferon alpha-2a , achieve target concentration Ribavirin &gt; 15 micromol W 12 , lead 90 % SVR ( 2 ) . All patient manage complete one year treatment period need EPO two transfuse . Patient 's global exposure Ribavirin evaluate area curve ( AUC ) seem pertinent term exposure-effect relationship measure Ribavirin level single time point . A recent study show HCV patient infect genotype 1 Ribavirin plasma exposure first dose ( i.e. , interdose AUC0-12h abbreviate AUC0-4h ) significantly strongly link SVR , whereas AUCs determine W12 W24 trough concentration Day 0 W12 ( 3 ) . Therefore , propose randomize controlled trial investigate whether adjust Ribavirin dos base AUC0-4h obtain D-7 600mg dose Ribavirin versus fix standard dos improve outcome treatment chronic hepatitis C naïve patient infect genotype 4 . Methodology : After AUC0-4h determine D-7 ( 7 day randomization ) 190 genotype 4 patient recruited trial , patient randomize two group : Group A : receive standard dose Ribavirin 1000-1200 mg/day ) Group B : receive adjusted-dose Ribavirin accord AUC0-4h . The individual calculate dose administered patient begin first day treatment . Both group receive combination treatment peginterferon alpha 2a 180 mcg/week total 48 week . Both treatment group receive Darbepoetin subsequent Hb &lt; 11 g/dl male female . Our main inclusion criterion : patient 18-70 year old serological evidence chronic hepatitis C positive HCV RNA genotype 4 , liver biopsy within 3 year prior recruitment . Our main exclusion criterion : decompensated cirrhotic patient , HBV/HIV co-infection , evidence hepatocellular carcinoma ( HCC ) , significant evolutive cardiovascular , pulmonary , renal psychiatric disease , pregnancy/breast feeding patient post liver transplantation anemia . Our primary outcome : HCV-RNA negativity 24 week end treatment ( SVR ) ( input adjust dose SVR ) . Our secondary outcome : rapid virological response ( RVR ) , early virological response ( EVR ) , partial early virological response ( pEVR ) , end treatment response ( ETR ) , relapse ( ETR ) , biochemical response safety tolerability high dos Ribavirin .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>1 . 1870 year age 2 . Chronic hepatitis C document detectable HCV RNA level PCR perform within 3 month A liver biopsy perform within 3 year fibro test/fibroscan within 1 year inclusion . 3 . Naive patient 4 . Genotype 4 5 . Compensated cirrhosis hepatitis C liver disease ( ChildPugh ≤ 6 ) 6 . Patient needing , accord physician , initiation combine therapy pegylated interferon alfa plus Ribavirin 7 . Negative HBsAg test HIVElisa test 8 . Negative pregnancy test baseline woman age procreation 9 . Efficient contraception along treatment period , 6 month discontinuation treatment woman men 1 . Decompensated Cirrhotic patient 2 . HBV HIV coinfection 3 . Evidence hepatocellular carcinoma 4 . Significant evolutive cardiovascular , pulmonary , severe psychiatric disorder renal dysfunction ( calculated creatinine CL &lt; 50 ml/min ) * . Patients meet trial criterion subsequent calculate creatinine CL &lt; 50 ml/min may need ribavirin dose reduction . 5 . Non compensate thyroid dysfunction 6 . Recent history epilepsy ( le 6 month ) 7 . Absolute contraindication one drug combination therapy 8 . Any noncompensated cardiac disease include ischemic heart disease Chronic cardiac failure ( grade III IV NYHA classification ) 9 . Uncontrolled high blood pressure ( SBP &gt; 180 mmHg inclusion spite hypertension treatment ) 10 . Pregnancy breast feed . 11 . Post liver transplantation patient HCV 12 . Alcohol drug induce liver disease . 13 . Metabolic autoimmune liver disease . 14 . Hemoglobinopathies anemia ; hemoglobin &lt; 12 gm /dl females &lt; 12.5 male correct erythropoietin 15 . Neutropenia ( &lt; 1500/mm³ ) 16 . Thrombocytopenia ( &lt; 90,000/mm3 ) , thrombocytosis ( &gt; 500,000/mm3 ) 17 . Patients evolutive diabetic hypertensive retinopathy . Patients stable include regularly follow treatment . 18 . Hypersensitivity epoetin beta one excipients 19 . Previous history increase risk venous thrombosis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>